ClinicalTrials.gg
Active, not recruitingNCT05285826Updated Dec 16, 2024

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

A Phase 3 interventional study of 9vHPV Vaccine and Placebo in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 34 sites in China. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,100
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Planned enrollment
4th of 31
8,100 · median 700
Started
2022
with 4 others
Phase 3
16 of 31
2 open now
Primary completion
2029-05
later than 16 of 19 live
Registered
22nd of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 4th largest by planned enrollment, is one of 5 that started in 2022, is one of 16 in phase 3, reaches primary completion later than 16 of the 19 other live ones, and was the 22nd registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be stratified by age and sexual orientation, and will have two stages. The primary hypothesis of Stage I is: 9vHPV vaccine reduces the combined incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related external genital and intra-anal 12-month persistent infection (PI) compared with placebo in males 20 to 45 years of age who are seronegative at Day 1 and polymerase chain reaction (PCR) negative from Day 1 through one month post-Dose 3 to the relevant HPV type. The primary hypothesis of Stages I and II combined is: 9vHPV vaccine reduces the combined incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related genital warts, penile/perianal/perineal intraepithelial neoplasia (PIN), or penile/perianal/perineal cancer compared with placebo in males 20 to 45 years of age who are seronegative at Day 1 and PCR negative from Day 1 through one month post-Dose 3 to the relevant HPV type.

03

Conditions studied

  • Papillomavirus Infections
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a Chinese male.
  • Has no more than 5 lifetime sexual partners.

Exclusion criteria

Exclusion Criteria:

  • Has a history of known prior vaccination with an HPV vaccine.
  • Has a history of HPV-related external genital lesions, HPV-related intra-anal lesions, or HPV-related head and neck cancer.
  • Has a history of severe allergic reaction that required medical intervention.
  • Has received immune globulin or blood-derived products in the past 3 months or plans to receive any before Month 7 of the study.
  • Has a history of splenectomy, is currently , or has been diagnosed with immunodeficiency, (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition.
  • Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical and certain regimens of systemic corticosteroids.
  • Has a known thrombocytopenia or coagulation disorder that would contraindicate IM injections.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8,100 participants (estimated)

Study arms

  • Experimental
    V503

    Participants will receive a single 0.5 mL intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.

    Biological: 9vHPV Vaccine

  • Placebo comparator
    Placebo

    Participants will receive a single 0.5 mL IM injection of placebo at Day 1, Month 2, and Month 6.

    Other: Placebo

Interventions

  • Biological9vHPV Vaccine

    9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection

    Also known as: V503

  • OtherPlacebo

    Sterile saline solution administered as a 0.5 mL IM injection

06

What researchers measure

Primary outcomes

  1. Stage I: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related External Genital and Intra-anal 12-month Persistent Infection

    This endpoint is defined as having occurred if a participant is positive for the same HPV type by the HPV PCR assay in the penile, scrotum, perineal, perianal and intra-anal swabs, biopsy, or excised samples obtained in 3 or more consecutive visits over a period of at least 12 months.

    Time frame: Up to approximately 30 months

  2. Stages I and II: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related Genital Warts, PIN, or Penile/Perianal/Perineal Cancer

    This endpoint is defined as having occurred if on a single biopsy or excised tissue from a participant, there is: (a) a pathology panel consensus diagnosis of genital warts, PIN of any grade, or penile/perianal/perineal cancer; and (b) detection of at least 1 of HPV types 6, 11, 16, 18, 31, 33, 45, 52 or 58 by Thinsection PCR in an adjacent section from the same tissue block.

    Time frame: Up to approximately 78 months

Secondary outcomes

  1. Stage 1: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related External Genital and Intra-anal 6-month Persistent Infection

    This endpoint is defined as having occurred if a participant is positive for the same HPV type by the HPV PCR assay in the penile, scrotum, perineal, perianal and intra-anal swabs, biopsy, or excised samples obtained in 2 or more consecutive visits over a period of at least 6 months.

    Time frame: Up to approximately 30 months

  2. Stage 1: Geometric Mean Titers (GMTs) to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at One Month Post-Dose 3

    GMTs to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 will be measured with a Competitive Luminex Immunoassay (cLIA).

    Time frame: Month 7

  3. Stage 1: Percentage of Participants Achieving Seroconversion to HPV 6, 11, 16, 18, 31, 33, 45, 52, or 58 at One Month Post-Dose 3

    A participant who changes serostatus from seronegative at Day 1 to seropositive at one month post-Dose 3 for a given HPV type is considered to have achieved seroconversion for that type. A participant with a titer at or above the seropositivity cutoff for a given HPV type, as measured by cLIA, is considered seropositive for that type.

    Time frame: Month 7

  4. Stage I: Percentage of Participants Who Report at Least 1 Solicited Injection-site Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Solicited injection-site AEs such as erythema, swelling, pain, and induration at the injection site will be recorded.

    Time frame: Day 1 through Day 8 following any vaccination

  5. Stage I: Percentage of Participants Who Report at Least 1 Solicited Systemic AE

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs.

    Time frame: Day 1 through Day 8 following any vaccination

  6. Stage I: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event.

    Time frame: Up to approximately 30 months

  7. Stages I and II: Combined Incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related Anal Intraepithelial Neoplasia (AIN) or Anal Cancer (MSM participants only)

    This endpoint is defined to have occurred if on a single biopsy or excised tissue from a participant, there is: (a) a pathology panel consensus diagnosis of AIN of any grade or anal cancer; and (b) detection of at least 1 of HPV types 6, 11, 16, 18, 31, 33, 45, 52 or 58 by Thinsection PCR in an adjacent section from the same tissue block.

    Time frame: Up to approximately 78 months

  8. Stages I and II: Percentage of Participants Who Experience at Least 1 SAE

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. An SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event.

    Time frame: Up to approximately 78 months

07

Study locations

34 sites
  • Beijing Youan Hospital ( Site 0001)
    Bejing, Beijing 100069, China
  • The Second Affiliated Hospital Chongqing Medical University ( Site 0052)
    Chongqing, Chongqing 400010, China
  • Chongqing Public Health Medical Center ( Site 0003)
    Chongqing, Chongqing 400036, China
  • The First Hospital of Lanzhou University ( Site 0034)
    Lanzhou, Gansu 730000, China
  • Southern Medical University Nanfang Hospital-Center for Drug Clinical Research ( Site 0031)
    Guangzhou, Guangdong 510515, China
  • The University of Hong Kong - Shenzhen Hospital ( Site 0049)
    Shenzhen, Guangdong 518053, China
  • Center for Disease Control and Prevention of Rong An ( Site 0046)
    Liuzhou, Guangxi 545400, China
  • Liucheng County Centers for Disease Control and Prevention ( Site 0045)
    Liuzhou, Guangxi, China
  • Wuhan Union Hospital ( Site 0032)
    Wuhan, Hubei 430022, China
  • Hunan Provincial Center for Disease Control and Prevention ( Site 0040)
    Changsha, Hunan 410005, China
  • The Third Xiangya Hospital of Central South University ( Site 0033)
    Changsha, Hunan 410013, China
  • Loudi Disease Prevention and Control Center Zhiyebing Prevention And Treatment Hospital ( Site 0015)
    Louxing District, Hunan 417000, China
  • Xiangtan Disease Prevention and Control Center ( Site 0030)
    XiangTan, Hunan, China
  • Xiangxiang Disease Prevention and Control Center ( Site 0016)
    Xiangxiang, Hunan, China
  • Qiyang Center for Disease Control and Prevention ( Site 0014)
    Yongzhou, Hunan 426100, China
  • The Second Hospital of Nanjing (Tangshan Branch) ( Site 0028)
    Nanjing, Jiangsu 2100003, China
  • The first affiliated hospital of China medical university ( Site 0041)
    Shenyang, Liaoning 110001, China
  • Liaoning University of Traditional Chinese Medicine Affiliated Hospital ( Site 0048)
    Shenyang, Liaoning 110031, China
  • Yuanqu Center for Disease Control and Prevention ( Site 0019)
    Yuncheng, Shanxi 043700, China
  • Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0018)
    Yuncheng, Shanxi 044000, China
  • Yongji Center for Disease Control and Prevention ( Site 0026)
    Yuncheng, Shanxi 044599, China
  • Ruicheng Center for Disease Control and Prevention ( Site 0025)
    Yuncheng, Shanxi 044600, China
  • Dazhu Disease Prevention and Control Center ( Site 0010)
    Dazhou, Sichuan 635100, China
  • Yuechi Disease Prevention and Control Center ( Site 0009)
    Guang'an, Sichuan 638399, China
  • Mianyang Center for Disease Control and Prevention ( Site 0007)
    Mianyang, Sichuan 621000, China
  • Santai County Center for Disease Control and Prevention ( Site 0008)
    Mianyang, Sichuan 621100, China
  • Neijiang Center for Disease Control and Prevention ( Site 0011)
    Neijiang, Sichuan 641000, China
  • Tianjin Second People's Hospital ( Site 0004)
    Tianjin, Tianjin 300192, China
  • Tianjin People' s Hospital ( Site 0038)
    Tianjin, Tianjin, China
  • Binchuan County Center for Disease Control and Prevention ( Site 0022)
    Dali, Yunnan 671600, China
  • Xiangyun County Center for Disease Control and Prevention ( Site 0021)
    Dali, Yunnan 672100, China
  • Yunnan Provincial Infectious Disease Hospital ( Site 0042)
    Kunming City, Yunnan 650111, China
  • First Affiliated Hospital of Kunming Medical University ( Site 0051)
    Kunming, Yunnan 650032, China
  • Zhejiang University School of Medicine - Affiliated Wenzhou Traditional Chinese Medicine Hospital (W
    Wenzhou Shi, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for May 2029, 87 months after the start.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's planned 87 months is above that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Mar 18, 2022
StartActual
Feb 18, 2022
Primary completionEst.
May 25, 2029
CompletionEst.
May 25, 2029
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05285826
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Feb 18, 2022
Primary completion
May 25, 2029 (estimated)
Completion
May 25, 2029 (estimated)
Last update
Dec 16, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion